{"name":"New England Retina Associates","slug":"new-england-retina-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ranibizumab injection and TTT - ICG based","genericName":"Ranibizumab injection and TTT - ICG based","slug":"ranibizumab-injection-and-ttt-icg-based","indication":"Wet age-related macular degeneration (AMD)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Topical Prednisolone Acetate 1%","genericName":"Topical Prednisolone Acetate 1%","slug":"topical-prednisolone-acetate-1","indication":"Inflammation and pain following ocular surgery","status":"marketed"}]}],"pipeline":[{"name":"Ranibizumab injection and TTT - ICG based","genericName":"Ranibizumab injection and TTT - ICG based","slug":"ranibizumab-injection-and-ttt-icg-based","phase":"phase_3","mechanism":"Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation.","indications":["Wet age-related macular degeneration (AMD)","Retinal vein occlusion (RVO)","Diabetic macular edema (DME)"],"catalyst":""},{"name":"Topical Prednisolone Acetate 1%","genericName":"Topical Prednisolone Acetate 1%","slug":"topical-prednisolone-acetate-1","phase":"marketed","mechanism":"Prednisolone acetate is a topical corticosteroid that suppresses local inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","indications":["Inflammation and pain following ocular surgery","Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye","Allergic conjunctivitis","Anterior uveitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9YWmZZSlB4eTJtenI4eTNHSy1BcXIxNFY2dks4RlVsVlVxQkNtR1d5ejFkMkh5T0FPMWNZbk9pZFBSZ01jbHB2Zzg0TE50WHdMNl8zcHVIdzAwVXVIZ0RwUg?oc=5","date":"2026-01-28","type":"pipeline","source":"The HIPAA Journal","summary":"HIPAA Violation Cases - Updated 2026 - The HIPAA Journal","headline":"HIPAA Violation Cases - Updated 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa0hEYU14cU9mUXE2SkNDTXJ6M2NTUjlRT1k4dnNNOFBxQ3drTDN2S1pjdDNzc1FSeTlFT2hNRmxCTm5hNGJlMlFfNElvckl0SklYMmptMjhqcHk4cl9oZlhwdVJ0czdZb0NKUVFrVE9pUUJGbVM1b2V1RGJJOW9sYkdwdjR3SFhwdlozQmUxaEhRWnVJLXcyT2NGcTZRZ3dNcE5BSV9Eajg0VEE1SjhabmlFdWpDSVJP?oc=5","date":"2025-10-09","type":"pipeline","source":"Ophthalmology Times","summary":"Increasing the knowledge base of GA is key to individualizing patient therapy - Ophthalmology Times","headline":"Increasing the knowledge base of GA is key to individualizing patient therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdVNUQWlKbExGT0ZHTVgtbExHYmw1dGtSdHU1cjN2Ymw5ME1QcnNRTkFWeFZSaEl4VkdnV3NKVlE0bFVhRVEwVE9fenZoQmJJbEZPUXlLb1hBTnhjVWlJTHZKa18wUGE3T3VNUnh5UUpfd3p4Y2NkZ2huajVySWFPX3lsSzZJV1RwelJqekIxRE5FSEpSb0tmM3dORmRxQjc3aXBhQmk0S0U?oc=5","date":"2025-06-03","type":"pipeline","source":"Healio","summary":"When should patients be referred to retina specialists? - Healio","headline":"When should patients be referred to retina specialists?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNVG5CU2xWVWZhbm5UVnVwem1VaDYtY2l0LTMyaFB6Nm1oV0Z6X2pHdnVCMXdZQlNiVDdPXzV4M0cyXzQ5eGRsamVfYk1mOFVYenp4QmlIajFhNGVmSmFhRV9XV2taZkZ1aDdEaTJ5Ml9WNzJMNS1nS0NMTE9mTnJGa2NxeGtEanZMUHdDVkw4ZGMxUQ?oc=5","date":"2024-12-23","type":"pipeline","source":"Ophthalmology Times","summary":"Advanced therapies for retinal vascular diseases - Ophthalmology Times","headline":"Advanced therapies for retinal vascular diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB0RXRadEdJcjBERi1SLXd4bnVEWkpHc2ZpYllaT3pUSTBvVmVzeENleHVaczV6Vkd3cnVqdlV4eDhkRVVOQUw2ZE5HREtqWEVvd3FJTzRiZzNlQnZJclFZ?oc=5","date":"2024-04-15","type":"pipeline","source":"nature.com","summary":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy - nature.com","headline":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9pZFRiZmlaYlhZd1dWZjlIaWQxdWxUR3U5LWI0WG0tTzB1d3pKTk9ZTVVWa0o0aE05Zkc2VnQtQ1VReEF5MklEWU1rMnNibWNMeG0ydFFFSlJMUHItS2MybVR3MA?oc=5","date":"2023-03-24","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Geographic Atrophy Overview - The American Journal of Managed Care® (AJMC®)","headline":"Geographic Atrophy Overview - The American Journal of Managed Care® (AJMC®)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOYjNuMkd6WmRyakNyWWFtb2pJWUhZLVhuWnFOMGFVMmwxTGlpbHNpRXlkbmM4NFhsZUZFcXBOYnlsdE93bHNSbC1YMmpFNDk2WFVGRWxBQl9lWm9VVEowc0lXWXVmMW5HN3Q1elFITnVRVkJfcjhxTmhJNTI2dE5ZN0gtUm1MME5IbGxPZTVDcldFeHNJUTV2U3VDWTY0dVNOX1pJYllyVnhMZU9TN0N2bDduSFg2MWg0Y2FsOWJ2RQ?oc=5","date":"2023-01-06","type":"pipeline","source":"masslive.com","summary":"Top donors for Maura Healey's inaugural bash include some entities she sued as AG - masslive.com","headline":"Top donors for Maura Healey's inaugural bash include some entities she sued as AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcVlyRjQxVGpxdkpZa1NNRmtONllVV0ZXemJ4QWtGT193OFc1bENHSGhKNzhzYng1NnBjVFdQXzgtZlFwQW1zUnJyTi1QT2hFSWFCMG5RMUh2YzU2ZWhyZUlUQzh6eElTelJLVlF6T0xCTzdvVGpQQ1piUWVTSmZUcndiTzRQVTdYNlJpTQ?oc=5","date":"2021-11-29","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Health Care Acquisitions – October 2021 - Private Equity Stakeholder Project PESP","headline":"Private Equity Health Care Acquisitions – October 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE44R2NuRTNmajB0SllwaUs5SnlqNFkxTmpfS0xNX2hGLXFOckN2N1ViaWtRUXRlOXI4QkV3UE54VURpbXUzeDJFOU9acnJvRFAzU3cyZ2RNd0VTd2gzUkJB?oc=5","date":"2006-10-05","type":"pipeline","source":"NEJM","summary":"Ranibizumab for Neovascular Age-Related Macular Degeneration - NEJM","headline":"Ranibizumab for Neovascular Age-Related Macular Degeneration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE41Sk15RXMtYWt0VWo2QTJpN0J0aXlsUnVNQmZRejRqalJnLVZITGtiMEJtRnhIZ210QjFQQXB0T0V5Q2swVHEwMDVrOGJ4dzFvdk1MZUdwTEEwVmZzWFE0?oc=5","date":"2004-12-30","type":"pipeline","source":"NEJM","summary":"Pegaptanib for Neovascular Age-Related Macular Degeneration - NEJM","headline":"Pegaptanib for Neovascular Age-Related Macular Degeneration","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}